Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 133

1.

Behavioral Determinants of Switching to Arsenic-Safe Water Wells: An Analysis of a Randomized Controlled Trial of Health Education Interventions Coupled With Water Arsenic Testing.

George CM, Inauen J, Perin J, Tighe J, Hasan K, Zheng Y.

Health Educ Behav. 2016 May 25. pii: 1090198116637604. [Epub ahead of print]

PMID:
27230268
2.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group.

N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.

PMID:
27119237
3.

The use of technology in Suicide Prevention.

Larsen ME, Cummins N, Boonstra TW, O'Dea B, Tighe J, Nicholas J, Shand F, Epps J, Christensen H.

Conf Proc IEEE Eng Med Biol Soc. 2015 Aug;2015:7316-9. doi: 10.1109/EMBC.2015.7320081.

PMID:
26737981
4.

Optimizing the management of patients with spinal myeloma disease.

Molloy S, Lai M, Pratt G, Ramasamy K, Wilson D, Quraishi N, Auger M, Cumming D, Punekar M, Quinn M, Ademonkun D, Willis F, Tighe J, Cook G, Stirling A, Bishop T, Williams C, Boszczyk B, Reynolds J, Grainger M, Craig N, Hamilton A, Chalmers I, Ahmedzai S, Selvadurai S, Low E, Kyriakou C; UK Spinal Myeloma Working Group.

Br J Haematol. 2015 Nov;171(3):332-43. doi: 10.1111/bjh.13577. Epub 2015 Jul 17.

PMID:
26184699
5.

Orofacial plasmacytosis: a management conundrum.

Madhavarajan S, Tighe J.

Br J Oral Maxillofac Surg. 2015 Apr;53(4):399-402. doi: 10.1016/j.bjoms.2014.12.019. Epub 2015 Mar 1.

PMID:
25740082
6.

Pulmonary hypertension in POEMS syndrome: resolution following radiotherapy.

Brewis MJ, Church AC, Peacock AJ, Thomson S, Tighe J, Johnson MK.

Pulm Circ. 2014 Dec;4(4):732-5. doi: 10.1086/678553.

7.

Suicide prevention in Australian Aboriginal communities: a review of past and present programs.

Ridani R, Shand FL, Christensen H, McKay K, Tighe J, Burns J, Hunter E.

Suicide Life Threat Behav. 2015 Feb;45(1):111-40. doi: 10.1111/sltb.12121. Epub 2014 Sep 16. Review.

PMID:
25227155
8.

Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in squamous cell carcinoma of the tongue: markers of nerve invasion?

Doumas S, Paterson JC, Norris PM, Tighe JV, Newman L, Bisase BS, Kolokotronis AE, Barrett AW.

Oral Maxillofac Surg. 2015 Mar;19(1):61-4. doi: 10.1007/s10006-014-0455-4. Epub 2014 Jul 11.

PMID:
25008036
9.

The effectiveness of a suicide prevention app for indigenous Australian youths: study protocol for a randomized controlled trial.

Shand FL, Ridani R, Tighe J, Christensen H.

Trials. 2013 Nov 20;14:396. doi: 10.1186/1745-6215-14-396.

10.

Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.

Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L, Hughes T, Michor F, Paul J, Drummond M, Holyoake TL.

Br J Haematol. 2013 Dec;163(5):674-6. doi: 10.1111/bjh.12532. Epub 2013 Aug 19. No abstract available.

PMID:
24032404
11.

Talking through the dead: the impact and interplay of lived grief after suicide.

McKay K, Tighe J.

Omega (Westport). 2013-2014;68(2):111-21.

PMID:
24673038
12.

Bilateral asynchronous renal cell carcinoma with metastatic involvement of the tongue.

Ghazali N, Davis C, Barrett AW, Tighe JV.

Case Rep Pathol. 2012;2012:729642. Epub 2012 Sep 12.

13.

Synchronous metastatic adenoid cystic and squamous cell carcinoma of the cervical lymph nodes 31 years after ablation of the primary palatal tumour.

Doumas S, Barrett AW, Carrillo M, Tighe JV.

Br J Oral Maxillofac Surg. 2013 Oct;51(7):e190-1. doi: 10.1016/j.bjoms.2012.07.010. Epub 2012 Aug 2.

PMID:
22858404
14.

Hemimandibulectomy and vascularized fibula flap in bisphosphonate-induced mandibular osteonecrosis with polycythaemia rubra vera.

Ghazali N, Collyer JC, Tighe JV.

Int J Oral Maxillofac Surg. 2013 Jan;42(1):120-3. doi: 10.1016/j.ijom.2012.03.019. Epub 2012 Apr 18.

PMID:
22520725
15.

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.

Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group.

Blood. 2012 Jun 7;119(23):5374-83. doi: 10.1182/blood-2011-11-392522. Epub 2012 Apr 12.

16.

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.

Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group.

Haematologica. 2012 Mar;97(3):442-50. doi: 10.3324/haematol.2011.043372. Epub 2011 Nov 4.

17.
18.

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group.

Blood. 2012 Jan 5;119(1):7-15. doi: 10.1182/blood-2011-06-357038. Epub 2011 Oct 20.

19.

Bilateral cerebellopontine angle lesions not always NF2: diagnostic pitfall.

Rao A, Lawrie A, Bodkin P, Tighe J, Kamel M.

Br J Neurosurg. 2012 Apr;26(2):275-7. doi: 10.3109/02688697.2011.603851. Epub 2011 Oct 4.

PMID:
21970782
20.

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group.

Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21.

PMID:
21940214
Items per page

Supplemental Content

Loading ...
Write to the Help Desk